In Re: Aggrenox Antitrust Litigation
Case Number:
3:14-md-02516
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Ahern & Associates
- Baker Donelson
- Baker & Miller
- Ballard Spahr
- Barrett Johnston
- Bass Berry
- Berger Montague
- Blank Rome
- Brenner Saltzman
- Capozzi Adler
- Carmody Torrance
- Cohen Milstein
- Cohen Placitella
- Connolly Wells
- Cowdery Murphy
- Day Pitney
- DiCello Levitt
- Faruqi & Faruqi
- Garwin Gerstein
- Gibson Dunn
- Girard Sharp
- Glancy Prongay
- Goodwin Procter
- Grant & Eisenhofer
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hayber McKenna
- Heim Payne
- Heins Mills
- Hilliard & Shadowen
- Hurwitz Sagarin
- Jones Day
- Kenny Nachwalter
- Labaton Keller
- Latham & Watkins
- Lauletta Birnbaum
- Levin Sedran
- Lockridge Grindal
- Lowey Dannenberg
- McCune Wright
- Milberg Coleman
- Miller Shah LLP
- Motley Rice
- Norton Rose
- Nussbaum Law Group
- Odom & Des Roches
- Pomerantz LLP
- Pullman & Comley
- Quinn Connor Weaver
- Reinhardt Wendorf
- Shipman & Goodwin
- Simmons Hanly
- Smith Segura
- Spector Roseman
- Stevens & Lee
- Stoll Berne
- Taus Cebulash
- White & Case
- Wiley Rein
- Winstead PC
- Zayas Law Firm
- Zimmerman Reed
Companies
- Aetna Inc.
- Association for Accessible Medicines
- Bi-Lo
- BlueCross BlueShield of Tennessee Inc.
- Boehringer Ingelheim
- Boehringer Ingelheim Vetmedica Inc.
- CVS Health Corp.
- Florida Blue
- Gyma Laboratories of America Inc.
- H‑E‑B LP
- Humana Inc.
- International Union of Painters & Allied Trades
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Teva Pharmaceutical Industries Ltd.
- The Cigna Group
- The Kroger Co.
- Winn-Dixie Stores, Inc.
Sectors & Industries:
-
October 29, 2019
Allergan's $750M Deal Among Pharma's Top Antitrust Payouts
A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.
-
February 25, 2019
Calif. County Can't Get Deal Over Stroke Medication Tossed
A Connecticut federal judge on Monday refused the Orange County District Attorney's request to dismiss a $54 million settlement between indirect purchasers of stroke prevention medicine and Teva Pharmaceutical and Boehringer Ingelheim in antitrust multidistrict litigation, saying the county did not show the court lacked jurisdiction over the parties.
-
July 20, 2018
Judge OKs $54M Aggrenox Settlement In Pay-For-Delay Suit
A Connecticut federal judge has signed off on a $54 million settlement between indirect purchasers of stroke prevention medicine Aggrenox and drugmakers Teva Pharmaceutical and Boehringer Ingelheim to end allegations the companies blocked generic alternatives to the drug from coming to the market.
-
June 14, 2018
Aggrenox Buyers Slam Insurers' Bid To Opt Health Plans Out
Indirect buyers of the stroke prevention medicine Aggrenox on Wednesday slammed a request by six insurance companies to opt out hundreds of potential class members from a $54 million settlement agreement over an alleged pay-for-delay scheme, saying the companies have failed to show they are authorized to make such a request.
-
June 11, 2018
Aggrenox MDL Nears End As Drug Cos. Reach Final Deal
Teva Pharmaceutical and Boehringer Ingelheim on Monday announced a settlement with the last remaining party accusing them of entering into an illegal pay-for-delay agreement to keep a generic version of the stroke prevention medicine Aggrenox off the market, paving the way for the multidistrict litigation in Connecticut federal court to close out.
-
June 04, 2018
Humana, Drug Cos. Settle In Aggrenox Pay-For-Delay Row
Insurer Humana Inc. told a Connecticut federal court Friday it reached a confidential settlement with Teva Pharmaceutical and Boehringer Ingelheim, so its claims that the drugmakers blocked generic alternatives to the stroke-prevention drug Aggrenox from coming to the market could be tossed.
-
April 13, 2018
Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug from coming to the market should get $18 million of the proposed $54 million settlement.
-
March 20, 2018
Blue Cross Unit Fights Sanctions Bid In Aggrenox MDL
Blue Cross and Blue Shield of Louisiana on Monday urged a Connecticut federal judge to nix a sanctions bid from Boehringer Ingelheim and Teva in multidistrict litigation over an alleged pay-for-delay scheme for a generic of Aggrenox, saying the motion has "lost urgency and importance" as a result of recent schedule changes.
-
February 28, 2018
Drug Cos. Want Blue Cross Unit Sanctioned In Aggrenox MDL
Boehringer Ingelheim and Teva have asked a Connecticut federal court to sanction Blue Cross and Blue Shield of Louisiana for allegedly dodging discovery in multidistrict litigation in which it's accusing the drugmakers of entering into a $120 million pay-for-delay deal aimed at blocking generic versions of the stroke-prevention medication Aggrenox.
-
February 06, 2018
Boehringer, Teva Fight Humana's Bid To Block Aggrenox Deal
Boehringer Ingelheim and Teva Pharmaceutical urged a Connecticut federal judge Monday to ignore objections raised by Humana to a $54 million settlement reached with a proposed class of indirect Aggrenox buyers over allegations the drug companies blocked generic alternatives to the stroke-prevention medication from hitting the market.